tapebrief
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

AFL · Q2 2025 Earnings

Aflac

Reported August 5, 2025

30-second summary

30-second take: Aflac printed $1.78 adjusted EPS on $4.16B revenue, with the headline -19% YoY revenue line distorted by remeasurement and FX rather than core deterioration — adjusted pretax earnings of $1,198M and a 13.7% adjusted ROE tell the real story. The substantive shift is in Japan: management is now explicitly framing premium decline as inflecting toward stabilization on the back of Miraito cancer insurance momentum, with the Japan head of sales asserting 2025 sales will exceed 2024. US total adjusted revenue grew a modest +2.6% (with sales +2.7%, NEP +3.4%, in-force +4.3%) as underwriting discipline trumps volume, and elevated holding-company liquidity is being held without apology given a flat yield curve.

Headline numbers

EPS

Q2 FY2025

$1.78

Revenue

Q2 FY2025

$4.16B

-19.0% YoY

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$4.16B-19.0%
EPS$1.78

Guidance

Prior quarter data unavailable — comparison not possible.

Segment performance

Q2 FY2025
SegmentQ2 FY2025YoY
Aflac Japan$2.472B-6.2%
Aflac U.S.$1.728B+2.6%
Aflac Japan Adjusted Pretax Earnings¥114,310 million
Aflac U.S. Adjusted Pretax Earnings$388 million

Capital & returns

Q2 FY2025
SegmentQ2 FY2025
Adjusted Book Value Per Share$51.78

Other KPIs

Q2 FY2025
SegmentQ2 FY2025
Adjusted Pretax Earnings$1,198 million
Adjusted Earnings Per Share (diluted)$1.78
Adjusted Return on Equity (quarterly)13.7%
Net Investment Income$1,081 million
Aflac U.S. Combined Ratio77.5%

Management tone

Management's posture this quarter is best described as measured confidence on Japan with no overcommitment elsewhere — a notable lift from the defensive framing that has characterized recent Japan commentary, but stopping well short of an acceleration narrative.

Japan moves from structural headwind to inflection candidate. For multiple quarters Japan premium decline has been framed as a structural drag to be managed; this quarter the language shifts to stabilization. Dan stated plainly: "There was a shift, in my opinion, in marketing and sales in terms of the job that they are doing. They are doing a better job overall than they were doing a year and a half ago." Combined with Yoshizumi's "I am confident that the 2025 sales will exceed that of 2024" and Miraito early reads, this is the first quarter the company is publicly underwriting a Japan recovery thesis rather than a stabilization-at-best thesis. The premium print at -1.1% (toward the better end of the guided range) gives the assertion modest empirical backing.

Capital deployment urgency has been dialed down deliberately. Prior framing positioned excess capital as something to opportunistically deploy across dividends, buybacks, and strategic uses. This quarter Max reframed: "you have a US dollar yield curve that is essentially flat, which means that the so-called tax of holding cash right now is not what it used to be... the rush to do so is not necessarily there to the same extent that it may have been in the past when yields were much, much lower." The signal: elevated holding-company liquidity is not idleness, it's a stance. Pre-funding yen debt at positive carry reinforces this is tactical, not stuck.

US growth is being constrained on purpose, not by market. Virgil's "some deliberate intentional actions where we are really looking to get the right type of business" paired with the +2.7% sales print at the low end of range tells you management is filtering, not chasing. The implicit promise of 4Q enrollment acceleration is the test.

Expense ratio discipline is louder despite tech spend. Japan expense ratio commentary has shifted from "managing a drag" to "contained at low end of 20-23% range despite continued technology projects" — a subtle but real lift in confidence on operational leverage from digital and Gen AI investments.

Recurring themes management leaned on this quarter:

Japan cancer insurance (Miraito) momentum as sales driver and competitive differentiatorJapan marketing and sales organizational transformation and agilityUS disciplined underwriting and quality mix prioritized over volumeCapital deployment flexibility and elevated holding company liquidity as deliberate strategic positioningJapan premium stabilization narrative emerging despite ongoing structural headwindsDigital transformation and Gen AI adoption accelerating operational leverage in Japan

Risks management surfaced:

US macro uncertainty impacting enrollment and group business demandJapan medical insurance competition intensification and sales underperformanceLapse and reissue activity uptick risk related to Miraito product refreshFX volatility and yen appreciation risk to Japan earnings translationCommercial real estate portfolio continued stress requiring reserve adjustments

What to watch into next quarter

Japan sales trajectory vs. Yoshizumi's commitment: 2H 2025 Japan sales must exceed 2H 2024 to validate the "2025 > 2024" assertion. Miraito quarterly run-rate is the cleanest read.

Japan premium trend: whether Q3 premium decline narrows from -1.1% or widens — the inflection thesis depends on the trend, not the level.

US 4Q enrollment: the "stronger second half driven by 4Q bookings" claim is falsifiable. Watch whether US sales growth steps above +2.7% in Q4.

Holding company cash deployment: management is signaling patience, but a yield curve steepening or a strategic action would change the posture quickly. Watch buyback pace.

Lapse activity tied to Miraito refresh: management flagged "would not be surprised if we see a little bit of an uptick in lapse" — track persistency disclosure for any deterioration that would offset Miraito sales momentum.

USP regulatory model approval: expected by March 31, 2026 — any update on timing or scope.

Sources

  1. Aflac Q2 2025 Financial Supplement, filed with SEC: https://www.sec.gov/Archives/edgar/data/4977/000000497725000133/afl063025-fabdocument.htm
  2. Aflac Q2 2025 earnings call commentary (Dan Amos, Max Brodén, Virgil Miller, Yoshizumi).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.